Edition:
United States

Omeros Corp (OMER.OQ)

OMER.OQ on NASDAQ Stock Exchange Global Market

20.88USD
4:00pm EDT
Change (% chg)

$-0.11 (-0.52%)
Prev Close
$20.99
Open
$20.99
Day's High
$20.99
Day's Low
$20.76
Volume
88,050
Avg. Vol
255,713
52-wk High
$27.07
52-wk Low
$7.20

Latest Key Developments (Source: Significant Developments)

Omeros announces pricing of public offering of common stock
Tuesday, 15 Aug 2017 09:17am EDT 

Aug 15 (Reuters) - Omeros Corp :Omeros announces pricing of public offering of common stock.Says public offering of 3.00 million common shares priced at $22.75per share.  Full Article

Omeros announces public offering of common stock
Monday, 14 Aug 2017 04:05pm EDT 

Aug 14 (Reuters) - Omeros Corp -:Omeros announces public offering of common stock.Says offering 3.00 million common shares.  Full Article

Omeros Corporation Q2 loss per share $0.33
Tuesday, 8 Aug 2017 04:02pm EDT 

Aug 8 (Reuters) - Omeros Corp :Omeros corporation reports second quarter 2017 financial results.Q2 loss per share $0.33.Q2 earnings per share view $-0.38 -- Thomson Reuters I/B/E/S.Q2 revenue $17.2 million versus I/B/E/S view $14.4 million.  Full Article

FDA grants orphan drug designation to Omeros’ OMS721
Friday, 4 Aug 2017 11:10am EDT 

Aug 4 (Reuters) - Omeros Corp ::FDA grants Orphan Drug Designation to Omeros’ OMS721 for treatment of IGA Nephropathy.Says co plans to begin enrolling patients in its Phase 3 registration trial in IGA nephropathy later in 2017​.  Full Article

Omeros says FDA grants breakthrough therapy designation to OMS721 for treatment of IgA Nephropathy
Tuesday, 13 Jun 2017 11:30am EDT 

June 13 (Reuters) - Omeros Corp ::FDA grants breakthrough therapy designation to Omeros’ MASP-2 inhibitor OMS721 for the treatment of IgA Nephropathy.Omeros' second phase 3 clinical program for OMS721 slated to begin this year.‍OMS721 is also being evaluated in a phase 3 clinical program for atypical hemolytic uremic syndrome​.‍OMS721 also being evaluated in a phase 2 clinical program for hematopoietic stem cell transplant-associated thrombotic microangiopathy​.One or more additional OMS721 phase 3 clinical programs planned to initiate this year in IgA nephropathy, stem cell transplant-associated TMA.Following discussions with FDA and European Medicines Agency, phase 3 program for OMS721 in atypical hemolytic uremic syndrome is in progress.Preparing to initiate manufacturing scale-up of its MASP-3 antibodies in advance of clinical trials.Omeros also expects to commercialize OMS721 for one or more therapeutic indications as a subcutaneous injection.Preliminary clinical evidence indicating that drug may demonstrate "substantial" improvement over existing therapies is required.  Full Article

Omeros completes IGA nephropathy cohort in OMS721 phase 2 clinical trial
Wednesday, 17 May 2017 07:00am EDT 

May 17 (Reuters) - Omeros Corp :Omeros announces completion of IGA nephropathy cohort in OMS721 phase 2 clinical trial.Omeros Corp - additional positive results support rapid advancement to phase 3 trial.Omeros Corp - consistent with all other OMS721 clinical trials, no significant safety concerns have been observed.Omeros Corp - most commonly reported adverse events in trial are fatigue and anemia.  Full Article

Omeros reports Q1 revenue $12.3 million
Wednesday, 10 May 2017 04:02pm EDT 

May 10 (Reuters) - Omeros Corp :Omeros Corporation reports first quarter 2017 financial results.Q1 loss per share $0.34.Q1 earnings per share view $-0.35 -- Thomson Reuters I/B/E/S.Q1 revenue $12.3 million versus I/B/E/S view $13.3 million.  Full Article

Omeros reports more positive data in OMS721 phase 2 trial in renal diseases
Thursday, 30 Mar 2017 07:00am EDT 

Omeros Corp : Omeros reports more positive data in OMS721 phase 2 trial in renal diseases . Phase 3 program slated for this year . Consistent with all other OMS721 clinical trials, no significant safety concerns have been observed . Preparing breakthrough application and phase 3 protocol for discussion with FDA; phase 3 trial in IGAN expected to begin this year .New data corroborate and expand on trial results reported in Q4 of 2016.  Full Article

Omeros to present results from dose-ranging stage of OMS721 Clinical Trial
Monday, 27 Mar 2017 07:00am EDT 

Omeros Corp : Omeros to present results from dose-ranging stage of oms721 clinical trial in atypical hemolytic uremic syndrome at world congress of nephrology . Omeros to present results from dose-ranging stage of oms721 clinical trial in atypical hemolytic uremic syndrome at world congress of nephrology . Omeros corp - mean change from baseline in platelet count was statistically significant as measured by area under curve .Omeros- renal replacement therapy able to be discontinued in 1 patient during oms721 treatment, renal function remained stable following completion of treatment.  Full Article

Omeros reports additional positive results from OMS721 Phase 2 trial
Wednesday, 1 Mar 2017 07:00am EST 

Omeros Corp : Omeros reports additional positive results from OMS721 phase 2 trial in patients with stem cell transplant-associated thrombotic microangiopathy . Omeros Corp - total of ten serious adverse events have been reported, none considered related to OMS721 treatment . Omeros Corp - two patients died of progression of cancer after less than three weeks of OMS721 treatment . Omeros Corp - one patient died of graft failure after completing study and positively responding to oms721 .Omeros Corp - none of these deaths was considered by investigators to be related to OMS721 treatment..  Full Article